Log in

Trillium Therapeutics Stock Price, News & Analysis (TSE:TRIL)

C$0.36
-0.03 (-7.69 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
C$0.35
Now: C$0.36
C$0.39
50-Day Range
C$0.35
MA: C$0.45
C$0.55
52-Week Range
C$0.32
Now: C$0.36
C$5.31
Volume33,100 shs
Average Volume26,297 shs
Market CapitalizationC$10.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-416-5950627

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$34,000.00
Cash FlowC$1.57 per share
Book ValueC$0.12 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$10.09 million
Next Earnings DateN/A
OptionableOptionable

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.


Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

What is the consensus analysts' recommendation for Trillium Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Trillium Therapeutics.

Has Trillium Therapeutics been receiving favorable news coverage?

Press coverage about TRIL stock has been trending negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Trillium Therapeutics.

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Canada Goose (GOOS), ProMetic Life Sciences (PLI), Acacia Communications (ACIA), Advanced Micro Devices (AMD), Micron Technology (MU), Square (SQ), Sphere 3D (ANY), Amedisys (AMED), Alexion Pharmaceuticals (ALXN) and Align Technology (ALGN).

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the folowing people:
  • Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
  • Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
  • Dr. Robert Uger, Chief Scientific Officer
  • Dr. Penka Petrova, Chief Devel. Officer
  • Dr. Yaping Shou, Chief Medical Officer

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$0.36.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of C$10.09 million and generates C$34,000.00 in revenue each year. View Additional Information About Trillium Therapeutics.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is http://www.trilliumtherapeutics.com/.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.


MarketBeat Community Rating for Trillium Therapeutics (TSE TRIL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel